Liu Xiaohan, Zhan Ping, Zhang Yang, Jin Huiying, Wang Youzhao, Yang Yujie, Wang Ziying, Wang Xiaojie, Xu Qianqian, Zhen Junhui, Sun Rong, Sun Jinpeng, Liu Min, Yi Fan
Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Department of Organ Transplantation, Qilu Hospital of Shandong University, Jinan, China.
J Am Soc Nephrol. 2024 Dec 1;35(12):1655-1670. doi: 10.1681/ASN.0000000000000446. Epub 2024 Jul 30.
Lysosomal-associated protein transmembrane 5 (LAPTM5) is increased in tubular epithelial cells in CKD. Conditional knockout of in tubules attenuates kidney fibrosis in mice with CKD. LAPTM5 contributes to tubular senescence by inhibiting WWP2-mediated ubiquitination of notch1 intracellular domain.
Tubular senescence is a major determinant of CKD, and identification of potential therapeutic targets involved in senescent tubular epithelial cells has clinical importance. Lysosomal-associated protein transmembrane 5 (LAPTM5) is a key molecule related to T- and B-cell receptor expression and inflammation. However, the expression pattern of LAPTM5 in the kidney and the contribution of LAPTM5 to the development of CKD are unknown.
mice and tubule specific– knockout mice were used to examine the role of LAPTM5 in tubular senescence by establishing different experimental mouse CKD models.
LAPTM5 expression was significantly induced in the kidney, especially in proximal tubules and distal convoluted tubules, from mice with aristolochic acid nephropathy, bilateral ischemia/reperfusion injury–induced CKD, or unilateral ureter obstruction. Tubule-specific deletion of inhibited senescence of tubular epithelial cells and alleviated tubulointerstitial fibrosis in aged mice. Moreover, deficiency ameliorated kidney injury and tubular senescence in mice with CKD. Mechanistically, LAPTM5 inhibited ubiquitination of notch1 intracellular domain by mediating WWP2 lysosomal degradation and then leading to cellular senescence in tubular epithelial cells. We also observed a higher expression of LAPTM5 in tubules from patients with CKD, and the level of LAPTM5 was correlated with kidney fibrosis and tubular senescence in people with CKD.
LAPTM5 contributed to tubular senescence by regulating the WWP2/notch1 intracellular domain signaling pathway and exacerbated kidney injury during the progression of CKD.
溶酶体相关蛋白跨膜5(LAPTM5)在慢性肾脏病(CKD)患者的肾小管上皮细胞中表达增加。肾小管条件性敲除LAPTM5可减轻CKD小鼠的肾纤维化。LAPTM5通过抑制WWP2介导的Notch1胞内结构域泛素化促进肾小管衰老。
肾小管衰老在CKD中起主要决定作用,识别参与衰老肾小管上皮细胞的潜在治疗靶点具有临床意义。溶酶体相关蛋白跨膜5(LAPTM5)是与T细胞和B细胞受体表达及炎症相关的关键分子。然而,LAPTM5在肾脏中的表达模式以及LAPTM5对CKD发生发展的作用尚不清楚。
通过建立不同的实验性小鼠CKD模型,利用野生型小鼠和肾小管特异性LAPTM5敲除小鼠研究LAPTM5在肾小管衰老中的作用。
在马兜铃酸肾病、双侧缺血/再灌注损伤诱导的CKD或单侧输尿管梗阻小鼠的肾脏中,尤其是近端小管和远端曲管中,LAPTM5表达显著上调。肾小管特异性缺失LAPTM5可抑制老年小鼠肾小管上皮细胞衰老并减轻肾小管间质纤维化。此外,LAPTM5缺陷改善了CKD小鼠的肾损伤和肾小管衰老。机制上,LAPTM5通过介导WWP2溶酶体降解抑制Notch1胞内结构域的泛素化,进而导致肾小管上皮细胞衰老。我们还观察到CKD患者肾小管中LAPTM5表达较高,且LAPTM5水平与CKD患者的肾纤维化和肾小管衰老相关。
LAPTM5通过调节WWP2/Notch1胞内结构域信号通路促进肾小管衰老,并在CKD进展过程中加重肾损伤。